Mode
Text Size
Log in / Sign up

Acupuncture and Celecoxib for Chronic Knee Pain: Genetic Factors May Influence ResponseNew Gene Test Predicts Who Gets Pain Relief From Acupuncture

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that GABRB3 genotype may influence acupuncture response in knee osteoarthritis, but verum and sham acupuncture showed no significant difference.

This randomized controlled trial enrolled 180 patients with chronic knee pain due to knee osteoarthritis. Participants were assigned to verum acupuncture (VA), sham acupuncture (SA), celecoxib (SC), placebo (PB), or a waiting list (WL). The primary outcome was efficacy assessed via VAS and WOMAC, with responders defined by minimally clinically important difference, over a 2-week follow-up.

No significant difference was observed between VA and SA for the primary outcome. However, among patients receiving acupuncture (VA and SA combined), those carrying the GABRB3 rs4906902 AG/GG genotype showed a significant association with superior analgesic effects (p < 0.05). Other genetic loci (OPRM1 rs1799971, COMT rs4680, BDNF rs6265) showed no correlation with acupuncture response.

Safety data were not reported. A key limitation is that the lack of difference between VA and SA required combining groups to achieve statistical power for genetic analysis. The study suggests that genetic polymorphisms at GABRB3 rs4906902 could influence the analgesic effect of acupuncture, but this is an association, not causation.

Clinically, these findings are preliminary and do not support a clear advantage of verum over sham acupuncture for chronic knee pain. The genetic association requires replication before any practice implications can be drawn.

Imagine sitting in a waiting room with aching knees. You have tried pills that make you drowsy. You have tried injections that wear off too fast. Now you are considering acupuncture. You wonder if it will work for you.

Many people believe acupuncture helps with pain. But not everyone feels relief. Some patients feel nothing at all. Doctors have struggled to explain why some people respond well while others do not.

This new research changes that thinking. Scientists found a specific gene that acts like a switch for pain relief. Knowing your gene type could help you choose the best treatment plan.

The Old Way Vs The New Way

For years, doctors treated knee pain the same way for everyone. They offered acupuncture or pills without checking your genetics first. This approach ignores the fact that our bodies are unique.

But here is the twist. A new study shows that one gene matters more than others. This discovery could end the guesswork in pain management. It means treatments can be tailored to your specific biology.

A Factory Analogy For Pain Signals

Think of your brain as a busy factory. Pain signals are trucks driving through the factory. Some trucks carry bad news about injury. Other trucks carry calming messages.

The GABRB3 gene acts like a traffic controller at a specific intersection. If the controller works well, the calming trucks move fast. If the controller is broken, the pain trucks clog the road. This study found that some people have a working controller while others do not.

What The Study Tested

Researchers studied 180 patients with chronic knee pain from osteoarthritis. They split the group into five teams. Some teams got real acupuncture. Others got fake acupuncture. Some took medication. A few waited without any treatment.

The team also scanned the brains of every patient. They looked for differences in brain structure. They also tested the patients for specific gene variations. This allowed them to see how genetics linked to pain relief.

The main finding surprised many experts. Only one gene showed a clear link to success. That gene is called GABRB3. Patients with a specific version of this gene felt much more relief from acupuncture.

The study combined real and fake acupuncture groups to get stronger results. Even with this combination, the genetic link remained clear. Patients with the right gene version had better pain control. Their brains also showed changes in key areas that manage pain.

This doesn't mean this treatment is available yet.

The Catch With Real World Use

There is a catch to this exciting news. The study was done in a controlled setting. It involved 180 patients who were carefully selected. Real life is often messier than a research study.

Doctors cannot test every patient for this gene before every visit. It is too expensive and time-consuming right now. The gene test exists, but it is not ready for every clinic.

If you have chronic knee pain, talk to your doctor about options. Ask if acupuncture is right for your situation. This study gives you a new reason to ask about personalized care.

It also explains why some treatments fail. If your genetics do not match the treatment, you might not feel better. Understanding this helps you set realistic expectations. It also helps you find a doctor who listens to your story.

More research is needed before this becomes standard care. Scientists must test this in larger groups of people. They also need to check if the test works in different populations.

Approval for a new genetic test takes time. Regulatory bodies must review the safety and accuracy. Until then, doctors will continue to use their best judgment. They will combine this new knowledge with experience and patient history.

The future of pain care looks brighter. We are moving toward treatments that fit your body. This shift honors the individual differences that matter most.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
The mechanisms underlying individual variability in acupuncture analgesia among patients with chronic pain remain unclear. This randomized controlled trial investigated the core mechanisms of differential responses to acupuncture from genetic, neuroimaging, and transcriptomic perspectives in patients with chronic pain due to knee osteoarthritis (KOA). A total of 180 KOA chronic knee pain patients were randomly assigned to verum acupuncture (VA), sham acupuncture (SA), celecoxib (SC), placebo (PB), or waiting list (WL) groups (36 each). Over 2 weeks, VA/SA received 10 sessions, SC/PB oral medication for 14 days, and WL no intervention. Baseline 3.0T MRI 3D-T1 scans and genotyping (GABRB3 rs4906902, OPRM1 rs1799971, COMT rs4680, BDNF rs6265) were performed. Efficacy was assessed via VAS and WOMAC; responders/non-responders were defined by minimally clinically important difference. Chi-square test, logistic regression, voxel-based morphometry (VBM), and Allen Human Brain Atlas-based partial least squares regression were used. No significant difference in primary outcomes was observed between VA and SA, so they were combined as the acupuncture group (AG) to enhance statistical power. Only AG had a significant association between GABRB3 rs4906902 AG/GG genotype and acupuncture response (p < 0.05); other loci showed no correlation. AG/GG carriers in AG had lower gray matter volume in caudate head, putamen, and ventral striatum, with higher GABRB3 expression in these regions. Genetic polymorphisms at GABRB3 rs4906902 could influence the analgesic effect of acupuncture treatment in patients with KOA chronic knee pain, with AG/GG genotype carriers exhibiting superior analgesic effects. This finding may be associated with pain-modulating brain regions' gray matter volume reduction and upregulation of GABRB3 gene expression.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.